Fig. 5

RBM15 enhances insulin resistance in vitro. a The expression level of RBM15 with the increase of glucose concentration. (*P < 0.05, ***P < 0.001 by ANOVA); b Western blot analysis to measure RBM15 protein levels in LO2 cells transfected with siNC and/or siRBM15. (****P < 0.0001 by ANOVA); c Global m6A level of RNA extracted from RBM15-knockdown LO2 cells was measured via m6A dot blot assays. RNAs were serially diluted and loaded equally with the amount of 400 ng, 200 ng and 100 ng. The intensity of dot blot represented the level of m6A modification. d, e Glucose uptake test of LO2 cells transfected with siRB15 or overexpression RBM15 and followed with or without 30-min insulin treatment. (**P < 0.01, ****P < 0.0001 by ANOVA); f, g LO2 cells were transfected with RBM15 siRNA or overexpression of RBM15 and followed with or without 100 nmol/L insulin stimulation for 30 min, PI3K, p-AKT, and p-ERK protein and their total protein levels were determined by Western blot